Urinary Exosome mRNA Isolation for AKI Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for acute kidney injury (AKI) face challenges with sensitivity and accuracy, particularly in early stages, and lack effective markers for predicting renal recovery, leading to delayed or incomplete recovery of kidney function.
Innovation Solution
A method involving the isolation and analysis of mRNA from urinary exosomes and microvesicles using a proprietary filter material to detect specific gene expression profiles, such as CALB1, CALM1, CFLAR, EGF, GSTA1, HIF1A, IL18, PKM, PPIA, RIPK1, and SLC12A1, to diagnose AKI severity and predict recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic tests measure plasma or serum biomarkers, then the diagnostic process is simple and widely applicable, but the sensitivity and accuracy are insufficient for early AKI detection
Solution Approach 1:
The patent uses urinary exosomes as intermediary carriers that contain and protect mRNA biomarkers from kidney damage. These exosomes serve as a mediator between the damaged kidney tissue and the diagnostic test, allowing detection of injury markers that would otherwise be undetectable in traditional blood tests, thereby improving sensitivity without requiring direct access to kidney tissue.
Solution Approach 2:
The patent extracts and isolates specific mRNA biomarkers from urinary exosomes, separating the diagnostic information from the complex biological matrix. This extraction process concentrates the relevant injury markers (such as KIM-1, NGAL, and other kidney-specific mRNAs) while removing interfering substances, enhancing measurement precision while maintaining a manageable test procedure.
2Loss of time
If diagnostic tests are performed early in AKI stages, then timely intervention is enabled, but the biomarker levels are too low to be detected by conventional methods
Solution Approach 1:
The patent performs preliminary enrichment and concentration of exosomes from urine samples before biomarker analysis. This preliminary action accumulates sufficient quantities of exosomes containing low-abundance mRNA biomarkers, enabling detection in early AKI stages when biomarker levels are minimal. The enrichment step ensures that even trace amounts of injury markers can be reliably detected, extending the diagnostic window to the earliest stages of kidney injury.
3Reliability
If multiple biomarkers are analyzed to improve diagnostic accuracy, then prediction capability enhances, but the test procedure becomes more complex
Solution Approach 1:
The patent combines multiple mRNA biomarker analyses into a single integrated exosome-based assay platform. By merging the detection of various kidney injury markers (KIM-1, NGAL, GST, and other renal-specific mRNAs) within one test system that utilizes exosomes as a common carrier, the patent achieves high diagnostic accuracy through multi-biomarker analysis while avoiding the complexity of running separate tests for each marker. The exosome isolation step serves all biomarkers simultaneously, streamlining the overall procedure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a sensitive and accurate diagnostic tool for early detection of AKI and prediction of renal recovery, enabling timely intervention and improving patient outcomes by identifying specific biomarkers associated with kidney damage and repair mechanisms.
Implementation Method 1
passing a vesicle containing biological sample obtained from said subject through a vesicle-capture material
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A~2B
AI summary
The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine and isolating corresponding mRNA in order to diagnose and treat acute kidney injury (AKI). In particular, certain embodiments relate to the method of capturing EMV from urine applied to a filter device that is capable of capturing EMV. Nucleic acids such as mRNA can be isolated from the EMV using an oligo(dT)-coated plate designed to accommodate the filter device and then used for further molecular analysis. Quantification of the collected nucleic acids may then be used in the diagnosis and/or treatment of IBD.